Understanding What Matters Most to Patients: Establishing the Validity of a Best-Worst Scaling Survey

CompletedOBSERVATIONAL
Enrollment

51

Participants

Timeline

Start Date

March 21, 2022

Primary Completion Date

September 26, 2023

Study Completion Date

September 26, 2023

Conditions
Hematologic Neoplasms
Interventions
OTHER

Assessment Surveys

Patients will complete surveys in three periods. An initial baseline survey, longitudinal assessments completed every 2 weeks over the course of the first three months on study (6 times maximum), and extended assessments that will happen every 3 months after the initial longitudinal period up to 2 years on the study (7 times maximum). Baseline questionnaire will collect demographic and background medical record information. Longitudinal assessments will consist of a BWS questionnaire (patients rate importance of 7 treatment goals), decisional conflict scales, EQ-5D-5L, distress thermometer, and items from PRO-CTCAE. Extended assessments will use same questionnaires as longitudinal assessments.

OTHER

Qualitative Interviews

Patients will participate in 2 interviews (1 initial interview, 1 follow up). These will be cognitive interviews focusing on establishing content validity for BWS questionnaire. Will establish patient understanding of questions asked in BWS, understanding of how preferences affect treatment decisions, expected outcomes, and feedback from patients on other potentially important attributes not included in BWS.

Trial Locations (1)

27514

Lineberger Comprehensive Cancer Center, Chapel Hill

All Listed Sponsors
collaborator

National Institute of Nursing Research (NINR)

NIH

lead

UNC Lineberger Comprehensive Cancer Center

OTHER